In this article, we will take a look at the 10 Best European Dividend Stocks To Buy.
Dividend payouts for MSCI Europe companies hit a record €407 billion in 2023, and they are set to grow even more in 2024, with an expected increase to €433 billion, up about 6.5%. According to Allianz Global Investors, the total dividend payout is expected to reach €460 billion by 2025, marking a 13% rise from 2023. The dividend yield is also climbing. It stood at 3.47% at the end of 2023 and could go up to 3.67% in 2024. This is still well above the yield on long-term German government bonds, even after bond yields shot up in 2022. German companies in the MSCI index paid out a 3.3% dividend in 2023, with a projected rise to 3.53% in 2024. Meanwhile, companies from Norway, though still at the top, are expected to see a slight decline in their yield, from 7.2% in 2023 to 6.4% in 2024.
Dividends have had a huge impact on overall equity performance in Europe. Over the last 40 years, about 36% of MSCI Europe’s total return has come from dividends. From 2019 to 2023, dividends made up almost half of the overall return, and from 2014 to 2018, they were responsible for most of it. On top of that, dividend-paying companies tend to have less volatile stock prices compared to those that don’t pay dividends.
Also Read: 10 Dividend Stocks For Steady Income and 10 Best Bank Stocks With High Dividends.
Global dividends hit a record $1.66 trillion in 2023, and they’re expected to reach $1.72 trillion in 2024, according to Janus Henderson. Dividend growth in 2023 was up 5%, with a 7.2% rise in Q4 alone. Banks were a major driver of this growth, delivering record payouts and benefiting from higher interest rates that boosted their margins. Although miners slowed down the overall growth, other industries like vehicles, utilities, software, food, and engineering showed strong performance, highlighting the value of having a diversified portfolio. Twenty-two countries saw record dividend payouts, with Europe (excluding the UK) and Japan playing a key role. The UK saw a 5.4% rise in dividends, and France, Germany, and Italy also set new records.
S&P Global Market Intelligence forecasted that Europe’s dividend payouts would hit €474 billion in 2024, which is a slight dip of 0.8% compared to last year. However, excluding special payments, ordinary dividends should rise by 4%, reaching a new high of €463 billion. Banks are leading the charge, making up 15% of the total dividend payouts, followed by capital goods and energy, both at 9%. The materials sector is set to see a 16% decrease in dividends, but it will still contribute about 6%, the same as utilities and food, beverage, and tobacco. The banking, capital goods, and pharmaceutical sectors are likely to see double-digit increases in their dividends, with banking staying strong at the top. On the flip side, the transportation sector might experience a steep 49% drop. That said, factors like geopolitical tensions and stubborn inflation might pose some risks for dividends in 2025.
An investor holding a check representing the dividends paid out by the investment trust.
Our Methodology
For this article, we used the Finviz stock screener to filter out European dividend stocks. We focused on picking stocks with a consistent record of paying dividends, offering dividend growth, and being financially stable to steer clear of yield traps. The list below is ranked in the ascending order of dividend yield as of December 20. We have also mentioned the number of hedge fund holders in each firm, which was sourced from Insider Monkey’s Q3 2024 database.
At Insider Monkey, we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here)
10. UBS Group AG (NYSE:UBS)
Dividend Yield as of December 20: 1.18%
Number of Hedge Fund Holders: 25
UBS Group AG (NYSE:UBS) is a global financial services company based in Zurich, Switzerland. The company works with individuals, businesses, and institutions, offering everything from wealth management and personal banking to investment advice and corporate banking. In June 2024, UBS wrapped up its $3.2 billion merger with Credit Suisse Switzerland. While Credit Suisse clients are now part of UBS, the full migration of most client transactions to the UBS platform is planned for 2025 and will be rolled out gradually.
Building on its strong foundation, UBS Group AG (NYSE:UBS) had a strong third quarter, reporting a $1.4 billion net profit. These results highlight the bank’s robust diversified business model, global scale, and continued progress with integration efforts. Revenue increased 9% year-over-year, with solid growth in the Americas and APAC, while invested assets grew 15% to $6.2 trillion. UBS also had a successful launch of its unified global alternatives unit, which established the bank as a top 5 player in the sector. In Switzerland, despite some challenges with net interest income, UBS continued supporting the economy by granting or renewing CHF 35 billion in loans during the quarter.
UBS Group AG (NYSE:UBS) has also taken steps to align its capital position with future growth and shareholder returns. By voluntarily phasing out remaining transitional capital adjustments earlier than planned, the bank has brought its CET1 capital ratio to 14.3%, in line with its guidance. This move maintains a strong balance sheet and does not affect ongoing share buybacks for 2024 or UBS Group AG (NYSE:UBS)’s medium-term plans for dividends and buybacks.
Reflecting its commitment to delivering value to shareholders, UBS announced a $0.70 per share dividend for 2023 on February 6, 2024 – an impressive 27% increase year-over-year. The dividend was distributed to shareholders on May 3. It is one of the best dividend stocks on our list.
9. Linde plc (NASDAQ:LIN)
Dividend Yield as of December 20: 1.31%
Number of Hedge Fund Holders: 63
Linde plc (NASDAQ:LIN) is a global industrial gas company offering gases like oxygen, nitrogen, helium, and hydrogen. It also designs and builds process plants for industries such as healthcare, chemicals, manufacturing, and electronics. Founded in 1879, Linde plc (NASDAQ:LIN) operates worldwide and is headquartered in Woking, United Kingdom. On November 1, 2024, BMO Capital Markets raised its price target for Linde plc (NASDAQ:LIN) from $477 to $507, maintaining an Outperform rating. The upgrade reflects Linde’s strong execution of its growth strategy, even amid broader economic challenges.
Linde plc (NASDAQ:LIN) reported a 2% rise in sales to $8.4 billion in the third quarter of 2024, driven by project activity and strong demand for liquefied natural gas infrastructure. The company also secured a major $2 billion contract with Dow Chemical, boosting its project backlog to a record $10 billion. Dow’s ambitious project aims for net-zero carbon emissions at its Alberta facility, transitioning from natural gas to low-carbon blue hydrogen. As an industrial partner, Linde plc (NASDAQ:LIN) will provide atmospheric gases, low-carbon hydrogen, and CO2 capture and off-gas cleanup services. For Q4 2024, Linde expects earnings per share between $3.86 and $3.96, with a full-year EPS forecast of $15.40 to $15.50, reflecting a 9-10% growth.
Linde plc (NASDAQ:LIN) announced a quarterly dividend of $1.39 per share on October 28. The dividend will be paid on December 17 to shareholders on record as of December 3. The company has a 31-year record of increasing dividends consistently.
Insider Monkey’s Q3 database shows that 63 hedge funds had long positions in Linde plc (NASDAQ:LIN). LIN is ranked 9th on our list of the best European stocks for an income portfolio.
8. AstraZeneca PLC (NASDAQ:AZN)
Dividend Yield as of December 20: 2.27%
Number of Hedge Fund Holders: 42
AstraZeneca PLC (NASDAQ:AZN) is a global pharmaceutical company focused on developing, producing, and selling prescription medicines. Its products treat a wide range of conditions, including cardiovascular, renal, metabolic, oncology, COVID-19, and rare diseases. Founded as Zeneca Group PLC in 1992, the company rebranded to AstraZeneca PLC in 1999 and is based in Cambridge, UK.
The company’s top products include Tagrisso for lung cancer, Farxiga for diabetes and heart failure, and Imfinzi for various cancers. These medications are major revenue drivers across both established and emerging markets, with Tagrisso alone bringing in $6 billion last year. AstraZeneca PLC (NASDAQ:AZN)’s Oncology portfolio sets the company on track to exceed analyst expectations by year-end, helping counter concerns about declining vaccine and immunotherapy revenues.
AstraZeneca PLC (NASDAQ:AZN) has upgraded its full-year guidance, now expecting total revenue and core EPS to grow by high-teen percent. The pharma giant reported strong global revenue distribution in the first nine months, with 43% from the US, 21% from Europe, 13% from China, and 14% from emerging markets outside China, which have outpaced China’s contribution. To drive further US growth as part of its 2030 ambition, AZN announced a $3.5 billion investment in US manufacturing and R&D.
AstraZeneca PLC (NASDAQ:AZN) recently acquired Gracell Biotechnologies, Fusion Pharmaceuticals, and Amolyt Pharma, focused on cell therapies for cancer, targeted radiopharmaceuticals for oncology, and endocrine and metabolic diseases. These acquisitions aim to strengthen the company’s oncology and biotechnology pipelines. Net debt rose by $3.8 billion, primarily due to acquisitions finalized earlier this year, and $4.6 billion was allocated for dividend payments.
At the end of Q3 2024, AstraZeneca PLC (NASDAQ:AZN) was held in 42 hedge fund portfolios, according to Insider Monkey’s database. Ken Fisher’s Fisher Asset Management held the biggest stake valued at $816.5 million.
7. Unilever PLC (NYSE:UL)
Dividend Yield as of December 20: 3.33%
Number of Hedge Fund Holders: 22
Unilever PLC (NYSE:UL) is a global consumer goods company with a broad portfolio across five key areas – Beauty & Wellbeing, Personal Care, Home Care, Nutrition, and Ice Cream. Its well-known brands include Dove, Hellmann’s, Ben & Jerry’s, and Knorr. Founded in 1860 and headquartered in London, Unilever serves markets worldwide, offering everything from skincare and hair care to ice cream and plant-based foods.
In Q3, Unilever PLC (NYSE:UL) saw a 4.5% increase in underlying sales and a 3.6% growth in volume. This marks the fourth quarter in a row of positive volume growth, with Beauty & Wellbeing and Ice Cream segments leading the charge. Ice Cream, in particular, is benefiting from ongoing operational improvements, although growth may not always be steady. The company’s Power Brands grew by 5.4%, driven by strategic investments under its Growth Action Plan (GAP), which has led to more consistent and stronger results across the business.
In Mar Vista Strategic Growth Strategy’s third-quarter 2024 investor letter, Unilever PLC (NYSE:UL) was highlighted as a key stock. The company saw a 25.49% increase in its stock price over the past 52 weeks, and as of December 2, 2024, its market capitalization stood at $148.31 billion. Here is what Mar Vista Investment Partners has to say about UL:
“We resumed our investment in Unilever PLC (NYSE:UL). We divested our Unilever position in 2022, following the company’s failed attempt to acquire GlaxoSmithKline’s (GSK) consumer health business. That proposed deal, characterized by its exorbitant price tag and a strategic shift from incremental to transformative acquisitions, eroded our confidence in Unilever’s capital allocation capabilities. The strategic misstep, coupled with a shareholder revolt and a negative stock price reaction, ultimately led management to abandon the acquisition.
Since our departure, Unilever has hired a new CEO and demonstrated a renewed commitment to enhancing shareholder value through a more disciplined approach to acquisitions and divestitures. Trian’s involvement in Unilever, including their investment and Nelson Peltz’s board position, has positively impacted the company’s capital allocation strategy…” (Click here to read the full text)
On October 28, Unilever announced a $0.4755 per share quarterly dividend. The dividend was distributed to shareholders on December 6. Unilever PLC (NYSE:UL) ranks 7th on our list of the best dividend stocks from the European market.
Famous Wall Street hedge funds including Fisher Asset Management, GQG Partners, and Arrowstreet Capital held significant stakes in Unilever PLC (NYSE:UL) as of September 2024. Overall, 22 hedge funds were bullish on the stock at the end of Q3.
6. Novartis AG (NYSE:NVS)
Dividend Yield as of December 20: 3.85%
Number of Hedge Fund Holders: 24
Novartis AG (NYSE:NVS) is a global leader in healthcare, involved in developing, manufacturing, and marketing prescription medications. Novartis covers a wide range of therapeutic areas such as oncology, immunology, cardiovascular, and ophthalmology, with key treatments like Pluvicto for prostate cancer and Lutathera for neuroendocrine tumors. The company is headquartered in Basel, Switzerland.
Novartis AG (NYSE:NVS) reported strong Q3 results, continuing two years of consistent growth. Sales increased by 10%, core operating income rose 20% in constant currency, and core margins reached 40.1%, prompting the company to raise its annual guidance for the third time. Key innovations included Kisqali’s FDA approval and CHMP positive opinion for early breast cancer, Fabhalta’s accelerated approval for IgA nephropathy, and promising developments for Pluvicto and Scemblix. Product highlights showed robust growth: Entresto’s sales climbed 26% globally, Cosentyx grew 28% with significant momentum in new indications, Kesimpta expanded by 56% (adjusted), and Kisqali’s U.S. sales surged 50%, supported by a Category 1 NCCN recommendation.
Novartis AG (NYSE:NVS)’s strategic moves included investments in research and development, artificial intelligence, and pipeline expansions, alongside shareholder returns through dividends and a $15 billion buyback plan, which will conclude by the end of 2025. Novartis AG (NYSE:NVS) continues to demonstrate strong financial performance, innovation, and market leadership, making it one of the best European stocks to consider.
Novartis AG (NYSE:NVS) stands out as a reliable choice for dividend-focused investors, offering a steady yield that has consistently grown over the years. Even though sales growth has been slow, the company is still super profitable and has been growing its dividends by an average of 4.26% annually, beating inflation. With its focus on innovation, strong finances, and undervalued stock price compared to competitors, Novartis is a smart choice long-term investment, with steady income and room for growth.
Novartis AG (NYSE:NVS)’s shares were held by 24 Wall Street funds at the end of the third quarter, compared to 30 funds in the preceding quarter. Jim Simons’ Renaissance Technologies is the leading stakeholder of the company, with 2.3 million shares worth $264.6 million.
5. HSBC Holdings plc (NYSE:HSBC)
Dividend Yield as of December 20: 4.14%
Number of Hedge Fund Holders: 14
HSBC Holdings plc (NYSE:HSBC), established in 1865 and based in London, is a global leader in financial services, operating through three key divisions – Wealth and Personal Banking, Commercial Banking, and Global Banking and Markets. It is one of the best European stocks to invest in.
HSBC Holdings plc (NYSE:HSBC) derives about half of its revenue from Asia, reflecting its strong focus on the region, with the rest coming from global operations like commercial banking and wealth management. In Q3 2024, the bank reported $17 billion in revenue, a $1.1 billion year-over-year increase, and announced $4.8 billion in shareholder returns, including a $0.10 per share dividend and a $3 billion share buyback. With a low PE ratio, HSBC appears undervalued and poised for growth. To enhance efficiency and address market challenges, HSBC plans $300 million in cost savings through senior-level job cuts, a restructuring of its banking operations, and the creation of a dedicated wealth division. Starting in 2025, the bank will split into East and West divisions, with Hong Kong and the UK functioning independently.
HSBC Holdings plc (NYSE:HSBC)’s UK operations had an exceptional year in 2024, achieving their best financial performance since the separation of retail and investment banking in 2018, with net profits surging over 80% year-on-year. The acquisition of Silicon Valley Bank’s UK division, now rebranded as HSBC Innovation Banking, has significantly boosted the bank’s net interest margin and fee income, contributing to its strong results.
Insider Monkey’s third quarter database indicates that HSBC Holdings plc (NYSE:HSBC) was found in 14 hedge fund portfolios, the same as the prior quarter. Ken Griffin’s Citadel Investment Group is the largest stakeholder in HSBC, with 687,682 shares worth $31 million.
4. Sanofi (NASDAQ:SNY)
Dividend Yield as of December 20: 4.27%
Number of Hedge Fund Holders: 32
Sanofi (NASDAQ:SNY) ranks 4th on our list of the best European stocks. Sanofi (NASDAQ:SNY), a Paris-based global healthcare company, develops and markets pharmaceuticals, vaccines, and consumer healthcare products. Its offerings include treatments for rare diseases, oncology, diabetes, cardiovascular conditions, and a variety of vaccines. Sanofi also provides over-the-counter products for colds, allergies, pain relief, and skin care. The company collaborates with leading firms to advance innovative therapies, including antibody-drug conjugates and genome editing technologies.
Sanofi (NASDAQ:SNY) reported a strong Q3, with sales reaching EUR 13.4 billion, reflecting a 16% increase at constant exchange rates. The growth was fueled by strong performances from Dupixent, which saw a global sales boost, and the vaccines business, especially Beyfortus, which showed strong uptake. New medicines launched by Sanofi, including ALTUVIIIO and Nexviazyme, contributed significantly to sales, further solidifying the company’s growth trajectory. Sanofi also highlighted positive Phase 3 results, including expansions for Dupixent in COPD and Bullous pemphigoid, which could drive future growth.
Sanofi (NASDAQ:SNY)’s operational improvements and strong gross margins led to a 19.9% rise in business operating income. The company has raised its 2024 earnings per share (EPS) guidance, reflecting the continued success of its strategy. Sanofi also reiterated its focus on shareholder returns through increased dividends and potential share buybacks. With solid year-on-year growth expected in Q4, Sanofi remains confident in its long-term outlook.
Ariel Global Fund stated the following regarding Sanofi (NASDAQ:SNY) in its Q3 2024 investor letter:
“French pharmaceutical company, Sanofi (NASDAQ:SNY) was another contributor over the quarter as momentum for Dupixent, a dermatitis treatment, drove earnings. Additionally, positive clinical trials for myeloma drug, Sarclisa and a Phase 3 Multiple Sclerosis asset also boosted shares. At current levels, we view Sanofi’s vaccines business as underappreciated and think the immunology pipeline is being overlooked. Also, we continue to be optimistic Dupixent will be a key growth driver.”
32 Wall Street hedge funds reported owning stakes in Sanofi (NASDAQ:SNY) at the end of the third quarter of 2024, with Ken Fisher’s Fisher Asset Management holding the biggest position, with 13.35 million shares worth nearly $770 million.
3. Shell plc (NYSE:SHEL)
Dividend Yield as of December 20: 4.54%
Number of Hedge Fund Holders: 48
Shell plc (NYSE:SHEL) is a global energy and petrochemical company operating across Europe, Asia, Oceania, Africa, the Americas, and the United States. Shell is advancing its energy strategy, with projects like Mero-3 in Brazil starting up and the divestment of Shell Pakistan to improve its portfolio. Nigeria has also approved a $1.3 billion deal allowing Renaissance Africa Energy, backed by local companies, to purchase Shell’s onshore oil assets in the country. The sale aligns with Shell’s long-term goal of exiting operations in the Niger Delta region.
Shell plc (NYSE:SHEL) remains focused on LNG and low-carbon oil, adapting to shifting demand in the marine sector. Shell plc (NYSE:SHEL) is also emphasizing operational efficiency and resilience, with Q4 cash flow impacted by the Pearl GTL turnaround but overall confident in its financial strength.
Shell’s LNG business is a key growth area, with projects like LNG Canada and Qatar LNG. The company is also seeing improved performance in marketing, generating higher earnings with the same crude prices. Capital investment for 2024 is expected to be between $22 billion and $25 billion, with a focus on high returns and flexibility. On the environmental front, Shell has made significant progress in reducing emissions, achieving a 70% reduction in methane emissions and 90% in routine flaring since 2016. The company is on track to meet its ambitious Scope 1 and 2 emissions reduction targets by 2030 and is committed to reducing Scope 3 emissions as well. Shell remains dedicated to creating more value with fewer emissions and will continue to prioritize sustainability in its strategy.
Shell plc (NYSE:SHEL) announced a quarterly dividend of $0.344 per share, and $0.688 per American Depositary Share (ADS), which was distributed on December 19. Shell plans to increase its annual dividend by approximately 4%, subject to board approval and aims to distribute 30-40% of its cash flow to shareholders through dividends and share buybacks.
Insider Monkey’s database suggests that 48 hedge funds held long positions in Shell plc (NYSE:SHEL), compared to 49 in the last quarter. Boykin Curry’s Eagle Capital Management is a prominent stakeholder in the company, with shares worth almost $997.5 million.
2. BP p.l.c. (NYSE:BP)
Dividend Yield as of December 20: 6.71%
Number of Hedge Fund Holders: 36
BP p.l.c. (NYSE:BP), headquartered in London since 1908, delivers energy solutions across multiple sectors. The company produces and trades natural gas, manages onshore and offshore wind energy projects, and develops hydrogen and carbon capture facilities.
BP p.l.c. (NYSE:BP) has made significant progress on its six priorities outlined earlier this year, pausing or halting 24 projects to refine its portfolio and focusing on competitive assets. New resource opportunities in Iraq, Azerbaijan, and Abu Dhabi are being explored, and cost-saving measures aim to achieve over $2 billion by 2026. The company remains committed to balancing growth in cash flow, capital discipline, and transitioning to cleaner energy through initiatives like biofuels, biogas, and EV infrastructure.
BP p.l.c. (NYSE:BP) reported strong operations in the third quarter, with upstream production up 3% year-to-date, including a 5% rise in liquid production. Upstream plant reliability exceeded 95%, and refining availability was over 96%. The company achieved 80% year-on-year growth in EV charging, delivering 1 terawatt-hour of electricity globally this year. BP also brought 23 kbd of biogas supply online, with additional plants set to launch in Q4. These efforts contributed to an underlying profit of $2.3 billion for the quarter, accompanied by a $1.75 billion share buyback and a $0.08 dividend per share.
In divestments, BP p.l.c. (NYSE:BP) is on track to meet its $25 billion target by 2025, having already announced $20 billion worth of sales. Meanwhile, acquisitions in transition growth engines like Bunge and Lightsource bp are now being integrated to maximize synergies over the next 12-18 months. The company reconfirmed a total of $7 billion in share buybacks for 2024, supported by a strong balance sheet and A+ credit ratings from Fitch and Moody’s.
BP p.l.c. (NYSE:BP) and Iraq have agreed on technical terms to redevelop the Kirkuk oil and gas field, with a final contract expected by early 2025. BP, which helped discover Kirkuk in the 1920s, aims to revive the neglected field as part of its upstream strategy. This follows a memorandum signed in August for broader investment in the region.
BP p.l.c. (NYSE:BP) is also a favorite stock of Wall Street hedge funds. In Q3 2024, 36 funds were bullish on BP p.l.c. (NYSE:BP), compared to 38 funds in the last quarter.
1. LyondellBasell Industries N.V. (NYSE:LYB)
Dividend Yield as of December 20: 7.29%
Number of Hedge Fund Holders: 38
LyondellBasell Industries N.V. (NYSE:LYB) is an American multinational chemical company incorporated in the Netherlands. The company operates globally across six segments – Olefins and Polyolefins, Intermediates and Derivatives, Advanced Polymer Solutions, Refining, and Technology. It produces and markets a variety of products, including polyethylene, polypropylene, propylene oxide, and advanced polymers, while also refining high-sulfur crude oil and developing chemical process technologies. LyondellBasell Industries N.V. (NYSE:LYB) is one of the best European stocks to buy for dividend investors.
LyondellBasell Industries N.V. (NYSE:LYB) delivered a solid performance in the third quarter despite challenging market conditions, maintaining strong safety standards, and advancing its long-term strategy. The company’s total recordable incident rate of 0.13 reflects its “GoalZERO” commitment to safety, surpassing industry benchmarks. Earnings for the quarter were $1.88 per share with EBITDA of $1.2 billion, supported by strong ethylene margins and improvements in its Americas Olefins and Polyolefins segment.
LyondellBasell generated $670 million in cash from operations, converted EBITDA to cash at 77%, and maintained a robust balance sheet with $2.6 billion in cash and $7.3 billion in liquidity. Despite weaker profits, the company returned $479 million to shareholders through dividends and buybacks while investing $368 million in capital projects. Its long-term strategy aims to build a profitable Circular & Low Carbon Solutions business, targeting an additional $1 billion EBITDA annually by 2030.
The company’s recent achievements include starting construction on the MoReTec-1 advanced recycling facility in Germany, supported by a €40 million EU Innovation Fund grant. This plant, expected to begin operations in 2026, will produce high-value circular polymers with reduced carbon footprints. LyondellBasell Industries N.V. (NYSE:LYB) remains on track to close its refinery by early 2025, transitioning from low-margin businesses to sustainable solutions.
As per Insider Monkey’s third-quarter hedge fund data, LYB was owned by 38 funds, compared to 41 funds in the earlier quarter. Cliff Asness’ AQR Capital Management is the largest stakeholder of the company, with 864,370 shares worth nearly $83 million.
Overall, LyondellBasell Industries N.V. (NYSE:LYB) ranks first on our list of the best European stocks. While we acknowledge the potential of LYB to grow, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LYB but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.